Biotechnology - Anti-virals, North America

Filter

Current filters:

Anti-viralsNorth America

Popular Filters

1 to 25 of 49 results

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

AHF claims victory over FDA on Gilead’s PrEP

19-02-2014

The USA-based AIDS Healthcare Foundation (AHF) says it has won another key legal victory late last week…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaRegulationTruvadaUSA

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

Call for Medicaid formularies to block Gilead’s $1,000 per pill hepatitis drug

30-01-2014

In a series of letters to be sent to state Medicaid directors starting this week, Michael Weinstein,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingSovaldiUSA

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

Gilead’s Sovaldi approved in Canada for Genotypes 1, 2, 3 or 4 HCV

16-12-2013

US antiviral biotech specialist Gilead Sciences says that Health Canada has issued a Notice of Compliance…

Anti-viralsBiotechnologyCanadaGilead SciencesNorth AmericaRegulationsofosbuvirSovaldi

US FDA backs new indication for Gilead's Complera

US FDA backs new indication for Gilead's Complera

14-12-2013

US biotech firm Gilead Sciences’ share closed up 1.6% at $71.40 on Friday, following the news of an…

Anti-viralsBiotechnologyCompleraEvipleraGilead SciencesNorth AmericaRegulation

US FDA approval for Gilead's hepatitis C drug Sovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi

08-12-2013

US antiviral biotech specialist Gilead Sciences says that the Food and Drug Administration has approved…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingRegulationsofosbuvirSovaldi

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

Unanimous yes vote from FDA advisory panel for Gilead’s sofosbuvir in hep C

27-10-2013

Following swiftly on a similar decision for Janssen’s hepatitis C drug simeprevir, the US Food and…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaRegulationsofosbuvir

Gilead's HIV combo drug Stribild shows viral suppression after three years

Gilead's HIV combo drug Stribild shows viral suppression after three years

16-10-2013

Gilead Sciences has announced results from two Phase III studies for its combination drug Stribild in…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaResearchStribild

Gilead’s HIV drug booster Tybost gets EU marketing authorization

Gilead’s HIV drug booster Tybost gets EU marketing authorization

27-09-2013

US biotech major Gilead Sciences has received marketing authorization from the European Commission for…

Anti-viralsBiotechnologyEuropeGilead SciencesNorth AmericaRegulationTybost

AHF claims victory over FDA in HIV prevention drug case

08-08-2013

The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

Idenix Pharma slumps as FDA calls for more data on IDX20963

24-06-2013

USA-based biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its share price plunge as much as 31.8%…

Anti-viralsBiotechnologyIdenix PharmaceuticalsIDX20963North AmericaRegulation

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

US and European gastroenterologist's views on hepatitis C treatments

02-05-2013

Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

US FDA delays approval of Gilead's elvitegravir and cobicistat for HIV

30-04-2013

US antiviral drug specialists Gilead Sciences (Nasdaq: GILD) says it has received Complete Response Letters…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaRegulation

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113

07-03-2013

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

1 to 25 of 49 results

Back to top